Found: 42
Select item for more details and to access through your institution.
Epigenetic therapy in lung cancer.
- Published in:
- Frontiers in Oncology, 2013, v. 3, p. 1, doi. 10.3389/fonc.2013.00135
- By:
- Publication type:
- Article
Addressing challenges with real-world synthetic control arms to demonstrate the comparative effectiveness of Pralsetinib in non-small cell lung cancer.
- Published in:
- Nature Communications, 2022, v. 13, n. 1, p. 1, doi. 10.1038/s41467-022-30908-1
- By:
- Publication type:
- Article
Antibody–Drug Conjugates in Non-Small Cell Lung Cancer: Emergence of a Novel Therapeutic Class.
- Published in:
- Current Oncology Reports, 2022, v. 24, n. 12, p. 1829, doi. 10.1007/s11912-022-01334-9
- By:
- Publication type:
- Article
Dashing Decades of Defeat: Long Anticipated Advances in the First-line Treatment of Extensive-Stage Small Cell Lung Cancer.
- Published in:
- Current Oncology Reports, 2020, v. 22, n. 2, p. 1, doi. 10.1007/s11912-020-0887-y
- By:
- Publication type:
- Article
Evidence to Date: Evaluating Pembrolizumab in the Treatment of Extensive-Stage Small-Cell Lung Cancer.
- Published in:
- Clinics & Practice, 2021, v. 11, n. 3, p. 441, doi. 10.3390/clinpract11030059
- By:
- Publication type:
- Article
The Effects of HER2 Alterations in EGFR Mutant Non-small Cell Lung Cancer.
- Published in:
- Clinical Lung Cancer, 2022, v. 23, n. 1, p. 52, doi. 10.1016/j.cllc.2021.08.012
- By:
- Publication type:
- Article
Antibody Drug Conjugates in Lung Cancer: State of the Current Therapeutic Landscape and Future Developments.
- Published in:
- Clinical Lung Cancer, 2021, v. 22, n. 6, p. 483, doi. 10.1016/j.cllc.2021.07.011
- By:
- Publication type:
- Article
Combining Osimertinib With Chemotherapy in EGFR-Mutant NSCLC at Progression.
- Published in:
- Clinical Lung Cancer, 2021, v. 22, n. 3, p. 201, doi. 10.1016/j.cllc.2021.01.010
- By:
- Publication type:
- Article
The Role of Performance Status in Small-Cell Lung Cancer in the Era of Immune Checkpoint Inhibitors.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Chemo-immunotherapy as first-line treatment for small-cell lung cancer.
- Published in:
- Therapeutic Advances in Medical Oncology, 2020, p. 1, doi. 10.1177/1758835920980365
- By:
- Publication type:
- Article
Current and Emerging Immunotherapies in SCLC: Promise and Challenges.
- Published in:
- Oncology (08909091), 2019, v. 33, n. 11, p. 439
- By:
- Publication type:
- Article
Association Between Smoking History and Overall Survival in Patients Receiving Pembrolizumab for First-Line Treatment of Advanced Non–Small Cell Lung Cancer.
- Published in:
- JAMA Network Open, 2022, v. 5, n. 5, p. e2214046, doi. 10.1001/jamanetworkopen.2022.14046
- By:
- Publication type:
- Article
Association Between Smoking History and Overall Survival in Patients Receiving Pembrolizumab for First-Line Treatment of Advanced Non–Small Cell Lung Cancer.
- Published in:
- JAMA Network Open, 2022, v. 5, n. 5, p. 1, doi. 10.1001/jamanetworkopen.2022.14046
- By:
- Publication type:
- Article
Novel Cytotoxic Chemotherapies in Small Cell Lung Carcinoma.
- Published in:
- Cancers, 2021, v. 13, n. 5, p. 1152, doi. 10.3390/cancers13051152
- By:
- Publication type:
- Article
Novel Targets in Advanced Non-Small Cell Lung Cancer.
- Published in:
- Clinical Advances in Hematology & Oncology, 2022, v. 20, n. 7, p. 426
- By:
- Publication type:
- Article
Pan-tumor survey of ROS1 fusions detected by next-generation RNA and whole transcriptome sequencing.
- Published in:
- BMC Cancer, 2023, v. 23, n. 1, p. 1, doi. 10.1186/s12885-023-11457-2
- By:
- Publication type:
- Article
Biomarkers predictive of response to pembrolizumab in head and neck cancer.
- Published in:
- Cancer Medicine, 2023, v. 12, n. 6, p. 6603, doi. 10.1002/cam4.5434
- By:
- Publication type:
- Article
A Phase I Trial of Dasatinib and Osimertinib in TKI Naïve Patients With Advanced EGFR-Mutant Non-Small-Cell Lung Cancer.
- Published in:
- Frontiers in Oncology, 2021, v. 12, p. 1, doi. 10.3389/fonc.2021.728155
- By:
- Publication type:
- Article
Effects of luteinizing hormone receptor signaling in prostate cancer cells.
- Published in:
- Prostate, 2015, v. 75, n. 2, p. 141, doi. 10.1002/pros.22899
- By:
- Publication type:
- Article
Effect of luteinizing hormone on the steroidogenic pathway in prostate cancer.
- Published in:
- Prostate, 2011, v. 71, n. 8, p. 892, doi. 10.1002/pros.21305
- By:
- Publication type:
- Article
Immunotherapy in lung cancer.
- Published in:
- Journal of Surgical Oncology, 2021, v. 123, n. 3, p. 718, doi. 10.1002/jso.26347
- By:
- Publication type:
- Article
Phase 1 study of the HSP90 inhibitor onalespib in combination with AT7519, a pan-CDK inhibitor, in patients with advanced solid tumors.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2020, v. 86, n. 6, p. 815, doi. 10.1007/s00280-020-04176-z
- By:
- Publication type:
- Article
A phase I trial of topotecan plus tivantinib in patients with advanced solid tumors.
- Published in:
- 2018
- By:
- Publication type:
- journal article
A Phase lb/ll Study of Ganetespib With Doxorubicin in Advanced Solid Tumors Including Relapsed-Refractory Small Cell Lung Cancer.
- Published in:
- Frontiers in Oncology, 2018, p. 1, doi. 10.3389/fonc.2018.00064
- By:
- Publication type:
- Article
NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types.
- Published in:
- British Journal of Cancer, 2022, v. 126, n. 3, p. 514, doi. 10.1038/s41416-021-01536-1
- By:
- Publication type:
- Article
NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Post-transplant outcomes of induction therapy for myeloma: Thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support.
- Published in:
- American Journal of Hematology, 2007, v. 82, n. 12, p. 1071, doi. 10.1002/ajh.21038
- By:
- Publication type:
- Article
Leptomeningeal carcinomatosis in sinonasal undifferentiated carcinoma.
- Published in:
- Head & Neck, 2013, v. 35, n. 11, p. E343, doi. 10.1002/hed.23225
- By:
- Publication type:
- Article
Neoadjuvant therapy for breast cancer.
- Published in:
- Journal of Surgical Oncology, 2010, v. 101, n. 4, p. 283, doi. 10.1002/jso.21446
- By:
- Publication type:
- Article
Safety and Efficacy of First‐Line Pembrolizumab in Black Patients with Metastatic Non‐Small Cell Lung Cancer.
- Published in:
- Oncologist, 2021, v. 26, n. 8, p. 694, doi. 10.1002/onco.13787
- By:
- Publication type:
- Article
Therapeutic Potential of Afatinib in NRG1 Fusion‐Driven Solid Tumors: A Case Series.
- Published in:
- Oncologist, 2021, v. 26, n. 1, p. 7, doi. 10.1634/theoncologist.2020-0379
- By:
- Publication type:
- Article
Comprehensive Genomic Profiling Aids in Distinguishing Metastatic Recurrence from Second Primary Cancers.
- Published in:
- Oncologist, 2017, v. 22, n. 2, p. 152, doi. 10.1634/theoncologist.2015-0511
- By:
- Publication type:
- Article
ERBB family fusions are recurrent and actionable oncogenic targets across cancer types.
- Published in:
- Frontiers in Oncology, 2023, p. 1, doi. 10.3389/fonc.2023.1115405
- By:
- Publication type:
- Article
Pembrolizumab-combination therapy for previously untreated metastatic nonsquamous NSCLC: Real-world outcomes at US oncology practices.
- Published in:
- Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.999343
- By:
- Publication type:
- Article
The Applicability of the Results in the Asian Population of ORIENT-11 to a Western Population According to the ICH-E5 Framework.
- Published in:
- Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.859892
- By:
- Publication type:
- Article
Reply.
- Published in:
- Acta Haematologica, 2011, v. 126, n. 4, p. 240, doi. 10.1159/000331465
- By:
- Publication type:
- Article
Therapy-Related Acute Myeloid Leukemia following Treatment with Trabectedin for Ewing's Sarcoma.
- Published in:
- Acta Haematologica, 2011, v. 126, n. 2, p. 76, doi. 10.1159/000324936
- By:
- Publication type:
- Article
Drugging KRAS: current perspectives and state-of-art review.
- Published in:
- Journal of Hematology & Oncology, 2022, v. 15, n. 1, p. 1, doi. 10.1186/s13045-022-01375-4
- By:
- Publication type:
- Article
Immune Checkpoint Inhibitors in Small Cell Lung Cancer: A Partially Realized Potential.
- Published in:
- 2019
- By:
- Publication type:
- journal article
BRCA1/2 Reversion Mutations in Patients Treated with Poly ADP-Ribose Polymerase (PARP) Inhibitors or Platinum Agents.
- Published in:
- Medicina (1010660X), 2022, v. 58, n. 12, p. 1818, doi. 10.3390/medicina58121818
- By:
- Publication type:
- Article
EGFR Mutations Are Not All the Same: the Importance of Biomarker Testing in Non-small Cell Lung Cancer (NSCLC)—A Podcast Discussion Between Patients and Oncologists.
- Published in:
- Oncology & Therapy, 2023, v. 11, n. 4, p. 419, doi. 10.1007/s40487-023-00242-7
- By:
- Publication type:
- Article
Oral Chemotherapy for Treatment of Lung Cancer.
- Published in:
- Frontiers in Oncology, 2020, v. 10, p. 1, doi. 10.3389/fonc.2020.00793
- By:
- Publication type:
- Article